Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibrx Biosciences (INBX) Non-Current Debt (2023 - 2025)

Inhibrx Biosciences (INBX) has disclosed Non-Current Debt for 2 consecutive years, with $100.6 million as the latest value for Q4 2025.

  • Quarterly Non-Current Debt changed N/A to $100.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $100.6 million through Dec 2025, changed N/A year-over-year, with the annual reading at $100.6 million for FY2025, N/A changed from the prior year.
  • Non-Current Debt for Q4 2025 was $100.6 million at Inhibrx Biosciences, up from $99.9 million in the prior quarter.
  • The five-year high for Non-Current Debt was $207.0 million in Q4 2023, with the low at $98.7 million in Q1 2025.